Excelsior Correspondent
JAMMU, Jan 1: Financial Commissioner, Health and Medical Education, Atal Dulloo, today chaired a meeting of Union Territory Level Adverse Events Following Immunization (AEFI) regarding COVID-19 vaccination programme scheduled to begin shortly across Jammu and Kashmir.
The meeting was attended by Director Health Services Jammu, Principal Government Medical College Jammu, Drug Controller J&K, HoDs Pediatrics, Medicine, Pharmacology, Microbiology, Pathology, Forensic, Anesthesia and SPM of GMC Jammu while Director Health Services Kashmir, Principal GMC Kashmir, HoDs Pediatrics, Medicine, Pharmacology, Microbiology, Pathology, Forensic, Anesthesia and SPM of GMCs Srinagar, Anantnag, Baramulla, Kathua, Rajouri, Doda, SKIMS Soura and JVC Bemina attended the meeting through video conferencing.
The meeting was also attended by the representatives of J&K Police, National Health Mission, J&K, Health Officers of Jammu Municipal Corporation and Srinagar Municipal Corporation besides other concerned officers.
State Immunization Officer, Dr Qazi Haroon, gave a detailed presentation about the development and the current stage of COVID-19 vaccine in the country. He informed the meeting that vaccine is expected to be introduced shortly for which two doses would be administered and second dose to be administered after 28 days of first dose.
He informed that senior doctors from majority fields of medicines have been included in the Adverse Event Following Immunization (AEFI) committee constituted for the COVID-19 vaccination programme, adding that it was for the first time that the committee will have experts to monitor and study the adverse health events after inoculation.
Regarding vaccination of the population and target groups, he said that a phase-wise strategy will be incorporated wherein health care workers have been identified followed by frontline workers of seven lakh population, adding that it would be followed by high risk population consisting greater than 50 years of age and less than 50 years of age associated with comorbid conditions.
He said in Phase-I, a total of around 28 lakh (2.8 million) population has been identified for the COVID-19 vaccination across Jammu and Kashmir. He added that detailed instructions on infection prevention and control practices during vaccination and management of minor, severe, serious AEFI would be issued.
Speaking on the occasion, FC H&ME, Atal Dulloo asked the concerned heads of GMCs and SKIMS to lay more emphasis on vaccination site and vaccination session parts which include waiting rooms, vaccination rooms and observation rooms.
He asked tertiary care hospitals viz SKIMS, Soura and eight GMCs of J&K to make a provision for a dedicated ward in their hospitals during vaccination session so that if any AEFI surfaces it would be resolved with timely intervention. He also asked them to follow all the AEFI Standard Operating Protocols so that no shortcoming would remain during the process.
Follow our WhatsApp channel